Evaxion Unveils Patented Genetic Adjuvant Technology for
Evaxion has developed genetic adjuvant technology that boosts immune responses to viral, bacterial and cancer vaccines
Preclinically validated for DNA and mRNA vaccines, and ready for clinical testing Significant market potential expected for DNA and mRNA vaccines against cancer, viral and bacterial diseases
COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of IA- of Immunotherapies, today unveils the technology behind its new proprietary genetic adjuvant developed to improve the efficacy of DNA and mRNA vaccines against infectious diseases and cancer.
The latest data from the adjuvant program was presented at Evaxion’s R&D Live Day on May 25, 2023.
“We are excited to introduce this novel genetic adjuvant technology to the global scientific community. It enhances Evaxion’s own DNA technology and has the potential to enhance the effect of virtually any vaccine. We foresee great market potential as this technology appears to be highly effective in DNA and mRNA-based vaccines against cancer as well as infectious diseases,” said Per Norlén, CEO of Evaxion.
Evaxion’s new genetic adjuvant is coded for CCL19, a molecule known to attract immune cells, including antigen-presenting cells, and can be encoded in DNA or mRNA vaccines to boost immune response .
The latest data show that genetic adjuvant technology enhances the antitumor effect in preclinical tumor models and induces neutralizing antibody and T cell responses against viral and bacterial antigens:
Administration of DNA or mRNA cancer neoantigen vaccines induced strong neoantigen-specific T cell responses and complete antitumor responses. virus (90% survival) Administration of Neisseria Gonorrhoeae antigenic DNA vaccine induced high antibody titers and specific T cell responses to bacterial antigens
Per Norlén continues: “By encoding the immunostimulatory molecule CCL19 in DNA or mRNA vaccines, we have demonstrated a significant improvement in vaccine efficacy. We believe this advance holds immense potential for vaccine development, as it stimulates both B-cell and T-cell immune responses, making it applicable to a wide range of vaccines. Building on the encouraging preclinical results, the next step is to validate the technology in patients.
Evaxion aims to bring the genetic adjuvant technology into clinical trials later this year as part of the EVX-03 personalized cancer immunotherapy program.
Go to the Investors section of the Evaxion website to access the replay of the R&D Day presentations.
Evaxion Biotech A/S is a pioneer in the development of AI-based immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune system to discover and develop new immunotherapies against cancer, bacterial diseases and viral infections. Evaxion has a broad pipeline of candidates, including three personalized cancer immunotherapies. It is located in Hørsholm, Denmark, and has 50 employees listed on the Nasdaq New York Stock Exchange. For more information, visit www.evaxion-biotech.com.
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target”, “believe”, “expect”, “hope”, “aim”, “intend”, “may”, “might”, “anticipate”, “contemplate”, ” continue”, “estimate”, “plan”, “potential”, “predict”, “project”, “will”, “may have”, “probable”, “should”, “could”, “might”, and d ‘other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of factors, including, but not limited to, risks relating to: our financial condition and our need for additional capital; our development work; the cost and success of our product development activities and preclinical and clinical trials; commercialize any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our reliance on third parties, including for the conduct of clinical trials and the manufacture of products; our inability to enter into partnerships; government regulations; protecting our intellectual property rights; employee issues and growth management; our ADSs and common stock, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business of the global COVID-19 pandemic and conflict in courses in the region around Ukraine and Russia; and other uncertainties affecting our business operations and financial condition. For a more in-depth discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the United States Securities and Exchange Commission (SEC), which are available at www.sec.gov. We undertake no obligation to update forward-looking statements, except as required by law.